728P Primary resistance (PrR) versus acquired resistance (AcR) to immune checkpoint inhibitors (ICI) in first-line metastatic renal cell carcinoma (mRCC)

Guida, A. ; Costa Silva, C. Alves ; Colomba-Blameble, E. ; Flippot, R. ; Salviat, F. ; Bracarda, S. ; Escudier, B. ; Albiges, L.

Elsevier Ltd

Texto completo disponível

1452MO Longitudinal analysis reveals gut microbiota shift during standard therapies in metastatic renal cell carcinoma (mRCC)

Alves Costa Silva, C. ; Piccinno, G. ; Cerbone, L. ; Iebba, V. ; Colomba, E. ; Flippot, R. ; C. Sow ; Darik, I. ; Maltez Thomas, A. ; Naoun, N. ; Bernard-Tessier, A. ; Reni, A. ; Segata, N. ; Escudier, B. ; Zitvogel, L. ; Albiges, L. ; Derosa, L.

Texto completo disponível

SO-22 Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study

Marmorino, F. ; Piccinno, G. ; Rossini, D. ; Ghelardi, F. ; Murgioni, S. ; Salvatore, L. ; Nasca, V. ; Antoniotti, C. ; Daniel, F. ; Schietroma, F. ; Conca, V. ; Costa Silva, C. Alves ; Tamburini, E. ; Tamberi, S. ; Passardi, A. ; Carullo, M. ; Antonuzzo, L. ; D'Onofrio, R. ; Zitvogel, L. ; Cremolini, C. ; Derosa, L.

Elsevier Ltd

Texto completo disponível

153P Prevalence and survival of stage IV male breast cancer: A SEER database analysis

Miguel-Semedo, P. ; Costa Lopes Pinto, C. ; Marques Da Costa, L.A. ; Ferreira, A.

Texto completo disponível

743P Activity of systemic therapies after cabozantinib (CABO) in patients (pts) with metastatic renal cell carcinoma (mRCC)

Cerbone, L. ; Di Nunno, V. ; Carril, L. ; Benchimol-Zouari, A. ; Flippot, R. ; Alves Costa Silva, C. ; Colomba-Blameble, E. ; Guida, A. ; Derosa, L. ; Escudier, B. ; Albiges, L.

Elsevier Ltd

Texto completo disponível

259MO A predictive score of cancer immunotherapy responses based on ecological analysis of gut microbiota

Derosa, L. ; Alves Costa Silva, C. ; Iebba, V. ; Routy, B. ; Reni, A. ; Audigier-Valette, C. ; Zalcman, G. ; Mazieres, J. ; Friard, S. ; Goldwasser, F. ; Moro-Sibilot, D. ; Scherpereel, A. ; Pegliasco, H. ; Martinez, S. ; Escudier, B. ; Planchard, D. ; Albiges, L. ; Besse, B. ; Barlesi, F. ; Zitvogel, L.

Elsevier Ltd

Texto completo disponível

1480P Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial

Colomba, E. ; Carril Ajuria, L. ; Dalban, C. ; Derosa, L. ; Alves Costa Silva, C. ; Rassy, E. ; Negrier, S. ; Chevreau, C.M. ; Gravis Mescam, G. ; Oudard, S. ; Laguerre, B. ; Barthelemy, P. ; Gross Goupil, M. ; Geoffrois, L. ; Thiery-Vuillemin, A. ; Joly Lobbedez, F. ; Ladoire, S. ; Tantot, F. ; Escudier, B. ; Albiges, L.

Texto completo disponível

Skeletal muscle loss as an adverse event during cabozantinib treatment in patients with metastatic renal cell carcinoma

Alves Costa Silva, C. ; Afonso, D. ; Colomba, E. ; Le Teuff, G. ; Derosa, L. ; Raynard, B. ; Guida, A. ; Benchimol-Zouari, A. ; Escudier, B. ; Bidault, F. ; Albiges, L.

Texto completo disponível

965P - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC)

Colomba, E. ; Alves Costa Silva, C. ; Le Teuff, G. ; Benchimol-Zouari, A. ; Guida, A. ; Derosa, L. ; Raynard, B. ; Escudier, B. ; Albiges, L.

Elsevier Ltd

Texto completo disponível

Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC)

Colomba, E. ; Alves Costa Silva, C. ; Le Teuff, G. ; Benchimol-Zouari, A. ; Guida, A. ; Derosa, L. ; Raynard, B. ; Escudier, B. ; Albiges, L.

Texto completo disponível